nz herald profiles dndn, page-10

Just for you Birdseye, for all your hard work :)

The path had already been choosen prior to Martins arrival.

It's a shame jack of all trades wasn't capable of being master of one "nick". He was a level headed poster imo.There dropping like flies. Goodluck Birdseye

""What was revealed in the Phase I trial results?
Previous attempts by scientists who developed the Prima technology
at the Austin Research Institute failed to achieve the
requisite T-cell response, with only an antibody response recorded.
However Prima's Phase trial in 10 patients with a range of advanced
malignancies showed that adding an adjuvant to the vaccine
allowed a cellular immune response to be recorded in all 10 patients and outstanding survival accounts in two of the patients in the trial.
The results were published in Clinical Cancer Research last month.
One 64 year-old woman in the trial had been diagnosed with
stage III ovarian cancer 26 months before enrolling in the study.
She had undergone surgery and been through six cycles of chemotherapy
treatment of carboplatin and paclitaxel. This woman may
have been expected to live for another 18 months. However,
after continuing with Prima's vaccine treatment well after completion
of the trial, the woman was clinically stable for three and
a half years. What was particularly impressive about this result
was the direct effect on CA125 (a marker for ovarian cancer)
levels following injection of the cancer vaccine, and it is this result
that has been a major reason that ovarian cancer was selected
as the target in the current Phase II trial.""

http://www.bioshares.com.au/research/bioshares159rbpprr.pdf